Research progress on treatment of myelodysplastic syndromes with demethylating drugs
10.3969/j.issn.1000-8179.2015.18.742
- VernacularTitle:骨髓增生异常综合征去甲基化治疗的研究新进展
- Author:
Huaquan WANG
;
Zonghong SHAO
- Publication Type:Journal Article
- Keywords:
myelodysplastic syndromes;
epigenetics;
methylation;
azacitidine;
decitabine
- From:
Chinese Journal of Clinical Oncology
2015;(18):895-899
- CountryChina
- Language:Chinese
-
Abstract:
Abnormal epigenetics play important roles in the pathogenesis of myelodysplastic syndromes (MDS). DNA hypermeth-ylation is the most common epigenetic abnormality in MDS. Demethylating DNA hypermethylation may improve the quality of life of MDS patients and prolong their overall survival. Azacitidine and decitabine are the demethylating drugs approved for MDS treatment. These drugs showed clinical effects on all subgroups of MDS patients.
